Skip To Main Content
Öner Tulum on Muck Rack

Öner Tulum

As seen in: The New York Times, Cambridge University Press & Assessment, Institute for New Economic Thinking
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Öner Tulum’s profile

Articles by Öner Tulum

Transforming Corporate Governance to Improve Access to Medicines in the Global South

|
By Padmashree Gehl Sampath, Öner Tulum, William Lazonick
| Institute for New Economic Thinking
Every year, millions of people die in the Global South from causes that are entirely preventable. Many of these deaths could be averted with timely and affordable access to medicines. According to the World Health Organization (WHO), of the roughly 2.7 billion people living in low-and middle-income countries (LMICs), more than two billion lack regular access to essential medicines.
Open in Who Shared Issue with article?

What Is a “Fair” Drug Price?

|
By William Lazonick, Öner Tulum
| Institute for New Economic Thinking
The ongoing negotiations under the Inflation Reduction Act over drug prices between Medicare and pharmaceutical companies confront the complex question of what constitutes a “maximum fair price” (MFP) for prescription medicine. The higher the price on a “MFP” drug under negotiation, the less affordable the drug is to the healthcare system.
Open in Who Shared Issue with article?

Sick with “Shareholder Value”: US Pharma’s Financialized Business Model During the Pandemic

|
By William Lazonick, Öner Tulum
| Institute for New Economic Thinking
Congress finally takes action, with the predictable PhRMA reaction On August 16, 2022, Congress passed the Inflation Reduction Act, which, among other things, enables Medicare to negotiate the prices of certain high-cost prescription drugs, beginning in 2026.[1] Even though it is just one step forward in confronting US pharma’s financialized business model, this legislation was a long time coming.[2] A New York Times article published almost four decades ago reported accusations against...
Open in Who Shared Issue with article?

Financialization of the U.S. Pharmaceutical Industry

|
By William Lazonick, Öner Tulum, Matt Hopkins, Mustafa Erdem Sakinç
| Institute for New Economic Thinking
Pharmaceutical drugs are often a matter of life or death. It should be a prime objective of government policy to rid the industry of financialization. Download as PDF Distributions to shareholders The performance of the U.S. economy depends heavily on the resource-allocation decisions of very large corporations.
Open in Who Shared Issue with article?

Opinion | How High Drug Prices Inflate C.E.O.s’ Pay

|
By William Lazonick, Öner Tulum
| The New York Times Verified
Pharmaceutical companies say their profits fund research and innovation in new medicines, but they are spending billions to enrich shareholders and executives. By William Lazonick and Öner Tulum Mr. Lazonick is an emeritus professor of economics at the University of Massachusetts, Lowell. Mr. Tulum is a postdoctoral fellow at SOAS, University of London. Feb.
Open in Who Shared Issue with article?

From Financialisation to Innovation in UK Big Pharma

|
By Öner Tulum, Antonio Andreoni, William Lazonick
| Cambridge University Press & Assessment
Hostname: page-component-cbd55998f-m6rrs Total loading time: 1.985 Render date: 2023-01-08T09:35:40.178Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true AstraZeneca and GlaxoSmithKline Published online by Cambridge University Press: Show author details Summary The tension between innovation and financialisation is central to the business corporation.
Open in Who Shared Issue with article?
Show More